How I treat primary cutaneous CD30+ lymphoproliferative disorders.

Abstract

The primary cutaneous CD30+ lymphoproliferative disorders are a family of extranodal lymphoid neoplasms that arise from mature postthymic T cells and localize to the skin. Current classification systems recognize lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma, and borderline cases. In the majority of patients, the prognosis of primary cutaneous CD30+ lymphoproliferative disorders is excellent; however, relapses are common, and complete cures are rare. Skin-directed and systemic therapies are used as monotherapy or in combination to achieve the best disease control and minimize overall toxicity. We discuss 3 distinct presentations of primary cutaneous CD30+ lymphoproliferative disorder and present recommendations for a multidisciplinary team approach to diagnosis, evaluation, and management of these conditions in keeping with existing consensus guidelines.

• Authors: Michi M Shinohara, Andrei Shustov
• Journal: Blood (Blood) Vol. 134 Issue 6 Pg. 515-524 (08 08 2019) ISSN: 1528-0020 [Electronic] United States
• PMID: 31164331 (Publication Type: Case Reports, Journal Article, Review)
• Copyright: © 2019 by The American Society of Hematology.

Chemical References

• Biomarkers
• Ki-1 Antigen

Topics

• Adult
• Aged
• Biomarkers
• Biopsy
• Combined Modality Therapy (methods)
• Female
• Humans
• Ki-1 Antigen (genetics, metabolism)
• Lymphoproliferative Disorders (diagnosis, etiology, therapy)
• Male
• Middle Aged
• Prognosis
• Skin Neoplasms (diagnosis, etiology, therapy)
• Symptom Assessment
• Treatment Outcome